Novakand Pharma AB (publ) (LARK) - Total Assets
Based on the latest financial reports, Novakand Pharma AB (publ) (LARK) holds total assets worth Skr57.56 Million SEK (≈ $6.19 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see LARK cash flow conversion for how efficiently the company converts equity into cash flow.
Novakand Pharma AB (publ) - Total Assets Trend (2012–2025)
This chart illustrates how Novakand Pharma AB (publ)'s total assets have evolved over time, based on quarterly financial data. See today's stock price for Novakand Pharma AB (publ) for real-time trading data and today's change.
Novakand Pharma AB (publ) - Asset Composition Analysis
Current Asset Composition (December 2025)
Novakand Pharma AB (publ)'s total assets of Skr57.56 Million consist of 11.7% current assets and 88.3% non-current assets. Explore Novakand Pharma AB (publ) short-term liquidity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 4.6% |
| Accounts Receivable | Skr436.00K | 0.8% |
| Inventory | Skr0.00 | 0.0% |
| Property, Plant & Equipment | Skr0.00 | 0.0% |
| Intangible Assets | Skr0.00 | 0.0% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Novakand Pharma AB (publ)'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Novakand Pharma AB (publ)'s current assets represent 11.7% of total assets in 2025, an increase from 2.7% in 2012.
- Cash Position: Cash and equivalents constituted 4.6% of total assets in 2025, up from 0.0% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 97.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 0.8% of total assets.
Novakand Pharma AB (publ) Competitors by Total Assets
Key competitors of Novakand Pharma AB (publ) based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Compagnie du Cambodge
PA:CBDG
|
France | €6.94 Billion |
|
Odyssean Investment Trust PLC
LSE:OIT
|
UK | GBX225.47 Million |
|
Australian Foundation Investment Company Ltd
AU:AFI
|
Australia | AU$9.82 Billion |
|
KBC Ancora
BR:KBCA
|
Belgium | €3.63 Billion |
|
IGM Financial Inc.
TO:IGM
|
Canada | CA$21.78 Billion |
|
Bajaj Holdings & Investment Limited
NSE:BAJAJHLDNG
|
India | Rs851.87 Billion |
|
Janus Henderson Group PLC
F:HDJA
|
Germany | €8.29 Billion |
|
L1 Group Limited
AU:L1G
|
Australia | AU$1.16 Billion |
Novakand Pharma AB (publ) - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.85 | 10.36 | 17.17 |
| Quick Ratio | 8.85 | 10.36 | 17.00 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr6.64 Million | Skr55.28 Million | Skr78.58 Million |
Novakand Pharma AB (publ) - Advanced Valuation Insights
This section examines the relationship between Novakand Pharma AB (publ)'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.78 |
| Latest Market Cap to Assets Ratio | 0.08 |
| Asset Growth Rate (YoY) | -25.2% |
| Total Assets | Skr56.73 Million |
| Market Capitalization | $4.79 Million USD |
Valuation Analysis
Below Book Valuation: The market values Novakand Pharma AB (publ)'s assets below their book value (0.08x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Novakand Pharma AB (publ)'s assets decreased by 25.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Novakand Pharma AB (publ) (2012–2025)
The table below shows the annual total assets of Novakand Pharma AB (publ) from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr56.73 Million ≈ $6.11 Million |
-25.23% |
| 2024-12-31 | Skr75.88 Million ≈ $8.17 Million |
-37.09% |
| 2023-12-31 | Skr120.61 Million ≈ $12.98 Million |
-23.77% |
| 2022-12-31 | Skr158.22 Million ≈ $17.03 Million |
-4.81% |
| 2021-12-31 | Skr166.22 Million ≈ $17.89 Million |
+109.31% |
| 2020-12-31 | Skr79.41 Million ≈ $8.55 Million |
+81.23% |
| 2019-12-31 | Skr43.82 Million ≈ $4.72 Million |
+24.78% |
| 2018-12-31 | Skr35.12 Million ≈ $3.78 Million |
+331.45% |
| 2017-12-31 | Skr8.14 Million ≈ $875.90K |
+66.47% |
| 2016-12-31 | Skr4.89 Million ≈ $526.15K |
-55.38% |
| 2015-12-31 | Skr10.96 Million ≈ $1.18 Million |
+75.39% |
| 2014-12-31 | Skr6.25 Million ≈ $672.31K |
+876.79% |
| 2013-12-31 | Skr639.58K ≈ $68.83K |
+7.55% |
| 2012-12-31 | Skr594.67K ≈ $64.00K |
-- |
About Novakand Pharma AB (publ)
Lärkberget AB (publ) operates as an investment company. The company is involved in direct investments in low-risk instruments, and unlisted profitable companies; financial investments; and reverse acquisition business. It also invests in listed shares, funds and other liquid asset classes, as well as participates in bridge loans and guarantee commitments. The company was formerly known as CombiGe… Read more